Acumen Pharmaceuticals, Inc.
sabirnetug (ACU193)
early Alzheimer's disease
Countdown
420days
Catalyst readout · ~ Aug 31, 2027 estimated
What's at stake
A key catalyst for sabirnetug (ACU193) (early Alzheimer's disease) is expected ~ Aug 31, 2027.
Primary source
· SEC 8-K
verified 15h ago
“Lead clinical candidate IND filing targeted for mid-2027”